Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Animal study shows chymase inhibitors could advance treatments for high BP and heart failure

Millions of patients with high blood pressure and heart failure take a class of drugs known as ACE (angiotensin-converting enzyme) inhibitors. These drugs prevent the body from processing angiotensin II, a hormone that constricts blood vessels.

26 Mar 2010

Study on zebrafish regenerate tissues links human heart implications

In a paper published in the March 25, 2010 issue of Nature, researchers working at the Salk Institute for Biological Studies and the Center of Regenerative Medicine in Barcelona (CMRB) identified a fish heart cell population that is the source of this astonishing healing feat, a finding that could provide insight into how mammalian hearts might be coaxed into repairing themselves after injury brought on by heart attack.

25 Mar 2010

Evotec AG reports financial results and corporate updates for 2009

Based on the Action Plan 2012, Evotec decided in March 2009 to strengthen its discovery alliances, creating the central vehicle for growth, and to implement strict cost cutting and restructuring measures. The Company reduced headcount in administrative and clinical development functions, reprioritised its R&D activities, concentrated its operations in Europe and closed the former facility of Renovis, Inc. in South San Francisco.

25 Mar 2010

High blood pressure lowers heart patients' death risk

Patients admitted to intensive heart care with chest pains have a better chance of surviving if they have high blood pressure. This is shown in a study by scientists at Linköping University in Sweden published in the world's largest medical journal JAMA.

24 Mar 2010

Bioheart to open five centers to provide cell therapy procedures for congestive heart failure patients

Bioheart, Inc., announced today plans for establishing five Centers of Excellence in Latin America to provide its cell therapy procedures to patients suffering from congestive heart failure and peripheral arterial disease beginning next month, April 2010. Bioheart entered into its first agreement with a leading treatment facilitator, Regenerative Medicine Institute of Tijuana, Mexico. Therapies for CHF and PAD patients will be made available at the Hospital Angeles Tijuana, a fully equipped state-of–the-art private specialties hospital. This will be the first of five Centers of Excellence with four additional Centers to be announced in the coming months.

24 Mar 2010

Celladon Corporation receives USPTO notice of allowance covering MYDICAR for advanced heart failure

Celladon Corp. announced today that the United States Patent and Trademark Office (USPTO) has granted a notice of allowance for a broad patent covering the company's lead drug candidate MYDICAR®, a genetically targeted enzyme replacement therapy for advanced heart failure. The patent will be issued to The Regents of the University of California and licensed exclusively to Celladon.

23 Mar 2010

$CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval$

CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval

Cell Therapeutics, Inc. announced today that the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee panel voted unanimously that clinical trial data was not adequate to support approval of pixantrone for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.

23 Mar 2010

Deborah Heart and Lung Center named Top Work Places 2010 and Best Hospital in New Jersey

Not once, but three times this week, Deborah Heart and Lung Center has been recognized as one of the best places to work and receive care. In three separate competitive reviews, Deborah, a specialty heart, lung, and vascular hospital in Browns Mills, has been recognized as a top workplace and top hospital.

22 Mar 2010

Sorin Group reports consolidated revenues of € 689.0M for 2009

“The final 2009 financial statements confirm the full achievement of our targets; this solid financial basis will be the foundation for future growth. The 2010-2014 Plan confirms the strategic guidelines previously communicated, based on profitability and cash flow expansion and prepares for accelerated growth in the future” said André-Michel Ballester, Chief Executive Officer, Sorin Group.

20 Mar 2010

FDA advisory panel recommends approval for Boston Scientific's CRT-D in treatment of mild heart failure

A new therapy that reduces the risk of mortality and heart failure in patients with mild cardiac disease received a thumb's up this week from an advisory panel to the U.S. Food and Drug Administration. The panel recommended that the cardiac resynchronization therapy defibrillator (CRT-D), tested extensively nationwide under the leadership of cardiologist Arthur Moss, M.D., professor of Medicine at the University of Rochester Medical Center, be approved for use in patients with mild heart failure in the United States.

20 Mar 2010

Overall mortality rates at Bay Medical Center in Panama City drop 1.3 points

Overall mortality rates from the end of 2007 to the beginning of 2010 at Bay Medical Center in Panama City, Florida have dropped from 3.4 to 2.1. A 1.3-point drop represents a huge reduction for any hospital and translates into lives saved.

19 Mar 2010

FDA approves expanded indication for Boston Scientific's CRT-Ds

Boston Scientific Corporation today announced that the Circulatory System Devices Panel of the U.S. Food and Drug Administration (FDA) has unanimously recommended approval of an expanded indication for its cardiac resynchronization therapy defibrillators (CRT-Ds), including the COGNIS® CRT-D. The panel recommended the expansion include the majority of the studied population of the landmark MADIT-CRT clinical trial, which evaluated the ability of these devices to slow the progression of heart failure in patients with asymptomatic or mild heart failure.

19 Mar 2010

Almost 62% of Canadians age 65 and older use five or more classes of prescription drugs: CIHI study

Almost two-thirds (62%) of Canadians age 65 and older living in the community in six provinces are using five or more classes of prescription drugs, according to a study released today by the Canadian Institute for Health Information.

19 Mar 2010

Physician scientists present new findings on aspirin therapy, atrial fibrillation drug therapy and LVAD

Physician scientists from the Cedars-Sinai Heart Institute presented new findings on the effectiveness of routine aspirin therapy for preventing heart disease, a drug therapy for atrial fibrillation and the role left ventricular assist devices may play in weight reduction for obese patients with chronic end-stage heart failure who are considered for heart transplantation.

19 Mar 2010

Bailout stenting successful treatment for infants with constricted aortas

Cardiac interventionalists and surgeons at University Clinic in Leuven, Belgium have achieved successful stent implantation and follow-up coarctectomy in premature infants suffering from aortic coarctation. Full findings are published in the March issue of Catheterization and Cardiovascular Interventions, the official journal of The Society for Cardiovascular Angiography and Interventions.

18 Mar 2010

USPTO allows Regulus Therapeutics' claims covering methods of antagonizing miR-181a for regulating immune response

Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in U.S. Application Serial No. 11/977,506 covering methods of antagonizing miR-181a to regulate immune response. This patent is owned by Stanford University and licensed exclusively to Regulus. miR-181a has been shown to regulate the response of immune cells, such as T lymphocytes, to specific stimuli and modulation of miR-181a could lead to a novel treatment of inflammatory disease.

18 Mar 2010

Medtronic's Advisa DR MRI SureScan pacemaker commercially available in selected European geographies

Medtronic, Inc. announced today the commercial availability of the Advisa DR MRI™ SureScan™ pacemaker in selected European geographies. The Advisa DR MRI SureScan pacemaker is the company’s second-generation pacemaker in a portfolio of devices from Medtronic designed, tested, and approved for use as labeled with MRI machines in selected European geographies.

18 Mar 2010

Studies link atmospheric CO pollution to adverse cardiovascular outcomes, cardiac mortality

In the healthy rat, prolonged exposure to carbon monoxide (CO) under conditions that mimic urban pollution leads to changes to cardiac morphology and function. Compensatory mechanisms develop in these animals to sustain normal cardiac activity, but they become more vulnerable to heart disease.

18 Mar 2010

Device manages care online for chronic disease patients

The Cleveland Plain Dealer: A pilot project at the Cleveland Clinic that monitored 250 patients with chronic diseases showed patients were able to increase the number of days between visits. The study used a medical device that shared daily patient data online with doctors and nurses and found that patients better managed their care using the system.

18 Mar 2010

Research data: WTC collapse caused potentially dangerous heart problems in responders on-site

Researchers from Mount Sinai School of Medicine are presenting more than 20 ground-breaking studies at the American College of Cardiology 59th annual scientific session (ACC.10) in Atlanta. Their research includes data showing that the World Trade Center collapse has caused potentially dangerous heart problems in responders on-site.

17 Mar 2010

Heart Failure News and Research

Further Reading

Animal study shows chymase inhibitors could advance treatments for high BP and heart failure

Study on zebrafish regenerate tissues links human heart implications

Evotec AG reports financial results and corporate updates for 2009

High blood pressure lowers heart patients' death risk

Bioheart to open five centers to provide cell therapy procedures for congestive heart failure patients

Celladon Corporation receives USPTO notice of allowance covering MYDICAR for advanced heart failure

CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval

Deborah Heart and Lung Center named Top Work Places 2010 and Best Hospital in New Jersey

Sorin Group reports consolidated revenues of € 689.0M for 2009

FDA advisory panel recommends approval for Boston Scientific's CRT-D in treatment of mild heart failure

Overall mortality rates at Bay Medical Center in Panama City drop 1.3 points

FDA approves expanded indication for Boston Scientific's CRT-Ds

Almost 62% of Canadians age 65 and older use five or more classes of prescription drugs: CIHI study

Physician scientists present new findings on aspirin therapy, atrial fibrillation drug therapy and LVAD

Bailout stenting successful treatment for infants with constricted aortas

USPTO allows Regulus Therapeutics' claims covering methods of antagonizing miR-181a for regulating immune response

Medtronic's Advisa DR MRI SureScan pacemaker commercially available in selected European geographies

Studies link atmospheric CO pollution to adverse cardiovascular outcomes, cardiac mortality

Device manages care online for chronic disease patients

Research data: WTC collapse caused potentially dangerous heart problems in responders on-site

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News